Hypertermic limb perfusion in lymphangiosarcoma Indications of hyperthermic limb perfusion (HILP) include unresectable limb soft tissue sarcoma, selected cases of malignant limb melanoma with multiple in-transit metastases, no distant metastases, and other, uncommon soft limb tumors, according to current Blue Book recommendations (7). We also include lymphangiosarcoma (sy Stewart-Tréves).
In our patient it was a woman of advanced age with the development of sarcoma at a distance of 21 years from the primary diagnosis of breast cancer and 15 years from the manifestations of lymphedema. The patient met the indication of locally advanced, unresectable sarcoma.
In addition to the biopsy, other sections of the so-called premalignant angiomatosis were apparent on the limb. The effect of the treatment was excellent, with a duration of complete regression of 12 months while maintaining full limb functionality.
It can be assumed that a new HILP could again have a therapeutic effect, but the patient does not want to repeat the procedure.